OP01

OP01 is a botulinum neurotoxin (BoNT) candidate being developed by Object Pharma specifically for the treatment of mental health disorders, with major depressive disorder (MDD) as its lead indication. Belonging to the same class of molecules as onabotulinumtoxinA, OP01 is designed to leverage the therapeutic potential of neurotoxins in psychiatric care. While the exact molecular target is not explicitly detailed on the company's website, botulinum neurotoxins typically function by cleaving SNARE proteins (such as SNAP-25), thereby inhibiting the release of neurotransmitters from synaptic vesicles. The development of OP01 represents an expansion of BoNT applications beyond traditional aesthetic and neuromuscular uses into the field of neuropsychiatry.

Other names

botulinum neurotoxin